|
|
Profile
|
Delegates :
Taro Tachibana |
|
Incorporated :
February 22 , 2022 |
Paid in Capital :
8 Million yen |
Employees :
2 members |
Address :
Sansei bldg. 4-12-14,Nishinakajima,Yodogawa-ku,Osaka City OSAKA
〒532-0011
|
TEL/FAX :
06-6777-9260 / |
URL：
|
Attachment :
|
Mission/Background :
We are a biotech startup founded in February 2022, originating from Osaka Metropolitan University (OMU) and Kobe University, specializing in drug seeds for pancreatic cancer treatment and diagnosis. We are developing monoclonal antibodies targeting pancreatic cancer stem cells, as well as those derived from unique patient cases.
Our CEO, who is also a professor at OMU, utilizes the university's advanced monoclonal antibody technologies in our efforts to combat pancreatic cancer.
|
|
Technology & Business
|
Technical Strength: Monoclonal Antibody Production Techniques
Our CEO has developed several novel monoclonal antibody production methods at his laboratory at OMU and at his affiliated company, Cell Engineering Corporation. The key methods include:
①\tShotgun Method based on iliac lymph node technique
②\tDNA Immunization Method for generating mouse or rat monoclonal antibodies
③\tSingle-Cell Method for generating rabbit monoclonal antibodies
④\tSingle-Cell Method for generating human monoclonal antibodies
These techniques enable the production of high-quality antibodies that are challenging for others to replicate.
We are actively developing antibody-based therapeutics for pancreatic cancer and are also producing and evaluating monoclonal antibodies against gemcitabine-resistant pancreatic cancer stem cells, as established at Kobe University.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
PT001: Monoclonal Antibody Targeting Cell Membrane Surface Antigens of Pancreatic Cancer Stem Cells
|
Discovery
|
Monoclonal antibody targeting pancreatic cancer stem cell surface antigens for pancreatic cancer treatment (PCT filed)
|
Data demonstrating efficacy and safety will be prepared, and out-licensing is planned at the preclinical stage
|
PT002: Monoclonal Antibody Derived from Special Pancreatic Cancer Patient
|
Discovery
|
Monoclonal antibody for pancreatic cancer treatment, produced using single-cell method from unique pancreatic cancer patients
|
Efficacy and safety data will be prepared, with Phase 1 trials conducted in-house, aiming for out-licensing after completion.
|
PT003: Monoclonal Antibody for Detecting Exosomes Released from Pancreatic Cancer Stem Cell
|
Discovery
|
Diagnostic agent seed for early-stage pancreatic cancer, detecting exosomes from cancer stem cells to enable Stage I diagnosis.
|
Sensitivity and specificity data from pancreatic cancer patient serum will be prepared, aiming for early out-licensing.
|
|
|
|
|
|
|
|
|
|
Highlights
|
PT001 was filed as a PCT application (PCT/JP2022/017037) in April 2022, with option agreements signed with the universities. We are currently evaluating its efficacy as both a standalone antibody and an antibody-drug conjugate (ADC).
Notable grants include the Osaka Prefecture "Drug Discovery Seeds Research and Development Subsidy" in 2023, funding from multiple banks, and support from the Japan Patent Office and other government agencies.
|
|
Alliance strategy
|
For PT001, we are seeking early out-licensing or collaboration opportunities. Interested companies working on pancreatic cancer treatments should contact us. We have data available on both the standalone antibody and its ADC form, subject to confidentiality agreements.
For PT003, we invite companies interested in developing early diagnostic tests for pancreatic cancer to reach out to us for potential collaboration or licensing opportunities.
|
|
|